Faron Pharmaceuticals Oy
FARN · AIM · Health Care · mcap £74m · 36.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 06 Oct 26 | Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board
Shareholders' Nomination Board re-elected with Timo Syrjälä as Chair. |
+0.0% | |
| 30 Sep 26 | Convertible bond amortization payment deferred by mutual agreement with HCM
Company defers EUR 1.4m amortisation payment on convertible bonds due October 2026 to April/December 2028. |
−3.9% | |
| 17 Sep 26 | Issuance of warrants
Faron issued 153,917 additional warrants to IPF Fund II following convertible bond amortisation. |
+0.0% | |
| 17 Sep 26 | Holding | Holding(s) In Company | |
| 07 Sep 26 | Holding | Holding(s) In Company | |
| 04 Sep 26 | Holding | Holding(s) In Company | |
| 26 Aug 26 | Results | Half-year Results
H1 2026 results show strengthened balance sheet with EUR 32m cash after EUR 40.1m rights issue to fund Phase 2b MDS trial. |
−2.4% |
| 19 Aug 26 | Notice of Half-Year Financial Results
Faron Pharmaceuticals will publish half-year results for January-June 2026 on 26 August 2026. |
+4.7% | |
| 05 Aug 26 | Holding | Holding(s) In Company | |
| 04 Aug 26 | Holding | Holding(s) In Company | |
| 03 Aug 26 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
Company settles EUR 1.58m bond amortisation via share issuance of 3.66m shares at EUR 0.4316. |
+0.0% |
| 27 Jul 26 | Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial
BEXMAB trial shows median overall survival not yet reached in two HR-MDS patient subgroups; 8.8 months in biallelic TP53 group. |
+2.5% | |
| 24 Jul 26 | Holding | Holding(s) In Company | |
| 01 Jul 26 | Routine | Grant of Options | |
| 22 Jun 26 | Holding | Holding(s) In Company | |
| 17 Jun 26 | Holding | Holding(s) In Company | |
| 17 Jun 26 | Holding | Holding(s) In Company | |
| 15 Jun 26 | Holding | Holding(s) In Company | |
| 11 Jun 26 | Holding | Holding(s) In Company | |
| 11 Jun 26 | Registration of Treasury Shares
Faron registered 21.5m treasury shares to prepare for future bond conversions. |
+0.0% | |
| 10 Jun 26 | Holding | Holding(s) In Company | |
| 08 Jun 26 | Holding | Holding(s) In Company | |
| 05 Jun 26 | Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee
Nasdaq Helsinki Disciplinary Committee fined Faron EUR 30,000 for breaching disclosure rules in 2024. |
−3.0% | |
| 04 Jun 26 | Holding | Holding(s) In Company | |
| 03 Jun 26 | Registration of New Shares
3.37 million new shares registered following exercise of Special Rights for EUR 1.60m. |
+0.0% | |
| 03 Jun 26 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
Company settles EUR 1.596m bond amortisation by issuing 3.366m shares at EUR 0.4741 per share. |
+0.0% |
| 01 Jun 26 | Holding | Holding(s) In Company | |
| 28 May 26 | Holding | Holding(s) In Company | |
| 28 May 26 | Issue of Treasury Shares to the Company
Board resolves to issue 21.5 million treasury shares to prepare for future bond conversions. |
+1.1% | |
| 28 May 26 | Special Rights attached to the First and Second Tranche of Bonds
Board issues 8,000,000 Special Rights attached to First and Second Tranche of Bonds. |
+1.1% | |
| 18 May 26 | Holding | Holding(s) In Company | |
| 06 May 26 | Termination of Liquidity Provision Service
Faron terminates liquidity provision agreement with Lago Kapital, effective 5 June 2026. |
−4.5% | |
| 05 May 26 | Holding | Holding(s) In Company | |
| 05 May 26 | Directorate Appointment
Dr. George Stanley Golumbeski appointed as Non-executive Director with immediate effect. |
+6.0% | |
| 04 May 26 | Result of AGM
Faron Pharmaceuticals Ltd: Results of the Annual General Meeting |
+6.0% | |
| 30 Apr 26 | Issuance of warrants
Faron issued 321,523 warrants to IPF Fund II following convertible bond amortisation. |
+7.2% | |
| 22 Apr 26 | Holding | Holding(s) In Company | |
| 20 Apr 26 | Holding | Holding(s) In Company | |
| 20 Apr 26 | Holding | Holding(s) In Company | |
| 16 Apr 26 | Holding | Holding(s) In Company | |
| 14 Apr 26 | Remaining offer shares registered with Finnish Trade Register
Remaining 41.9 million offer shares registered with Finnish Trade Register following April offering. |
−2.2% | |
| 14 Apr 26 | Registration of New Shares
3.6m new shares registered from special rights exercise; 41.9m shares from rights issue also registered today. |
−2.2% | |
| 13 Apr 26 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
3.6m new shares issued to bondholders at EUR 0.4516 per share in settlement of bond amortisation payments. |
+4.4% |
| 10 Apr 26 | Notice Of Faron Pharmaceuticals Ltd’s Annual General Meeting
Annual General Meeting scheduled for 4 May 2026 to approve 2025 financial statements and elect board members. |
−11.2% | |
| 10 Apr 26 | New shares registered with Finnish Trade Register
Registration of 38,055,229 new shares with Finnish Trade Register following share offering completion. |
−11.2% | |
| 09 Apr 26 | Results | Faron publishes final results of its EUR 40.1 million rights issue
Faron raised EUR 40.1 million gross proceeds through rights issue of 80.16 million shares at EUR 0.50 per share. |
−8.4% |
| 08 Apr 26 | Results | Inside Information: Faron publishes preliminary results of its successful rights issue
Rights issue of EUR 40.1 million completed with 52.33% subscription and cornerstone commitments securing full funding. |
+4.9% |
| 31 Mar 26 | Director dealing | Director/PDMR Shareholding | |
| 30 Mar 26 | Suspension - Faron Pharmaceuticals Oy | +1.1% | |
| 26 Mar 26 | Faron appoints new CTO to strengthen late-stage development activities
Faron appoints Heikki Jouttijärvi as Chief Technical Officer to support late-stage development of bexmarilimab. |
+1.2% | |
| 25 Mar 26 | Director dealing | Director/PDMR Shareholding | |
| 24 Mar 26 | Holding | Holding(s) In Company | |
| 19 Mar 26 | Director dealing | Director/PDMR Shareholding | |
| 19 Mar 26 | Director dealing | Director/PDMR Shareholding | |
| 19 Mar 26 | Director dealing | Director/PDMR Shareholding | |
| 12 Mar 26 | Holding | Holding(s) In Company | |
| 11 Mar 26 | The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
Finnish Financial Supervisory Authority approved prospectus for EUR 40 million rights offering. |
−4.5% | |
| 11 Mar 26 | Holding | Holding(s) In Company | |
| 10 Mar 26 | Inside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway
Faron announces fully covered EUR 40m rights offering at EUR 0.50 per share to fund Phase II trial and extend runway to November 2027. |
+4.9% | |
| 09 Mar 26 | Update to Faron’s Financial Calendar and date of the Annual General Meeting in 2026
Annual General Meeting rescheduled from 30 March to 4 May 2026. |
−4.7% | |
| 04 Mar 26 | Results | Faron Pharmaceuticals Ltd’s Annual Report 2025 published
Corrected Annual Report 2025 published with previously missing auditor's report included. |
+13.7% |
| 04 Mar 26 | Results | Faron Pharmaceuticals Ltd’s Annual Report 2025 published
Annual Report 2025 published. |
+13.7% |
| 04 Mar 26 | Faron’s Financial Statements Release 1 January to 31 December 2025
Faron reported 2025 results with continued bexmarilimab progress, orphan drug designations, and EUR 40m fundraising planned. |
+13.7% | |
| 02 Mar 26 | Result of General Meeting
TURKU - FINLAND 2 March 2026 – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the extraordinary |
−6.1% | |
| 09 Feb 26 | Notice To The Extraordinary General Meeting
Extraordinary General Meeting scheduled for 2 March 2026 to authorise Board to issue up to 80m shares via rights offering. |
−1.5% | |
| 09 Feb 26 | Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones
Faron Pharmaceuticals planning EUR 40 million rights offering to fund bexmarilimab development and Phase II/III trial. |
−1.5% | |
| 03 Feb 26 | Registration of New Shares
909,517 new shares registered following exercise of special rights at EUR 1.70 per share. |
−1.5% | |
| 03 Feb 26 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
Company issued 909,517 shares to settle EUR 1.55m of bond amortisation payments through share settlement option. |
−1.5% |
| 13 Jan 26 | Director dealing | Director/PDMR Shareholding | |
| 08 Jan 26 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
Company converts EUR 846,943 of First Tranche Bond amortisation into 453,979 treasury shares. |
+4.0% |
| 17 Dec 25 | Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board
Shareholders' Nomination Board re-elected with Timo Syrjälä as Chair. |
+0.0% | |
| 11 Dec 25 | Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement
Faron issues EUR 10 million second tranche of convertible bonds due December 2028. |
+0.0% | |
| 04 Dec 25 | Holding | Holding(s) in Company | |
| 03 Dec 25 | Registration of New Shares
517,795 new shares registered following exercise of Special Rights at EUR 965,998.35. |
+0.0% | |
| 03 Dec 25 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds
Company issues 517,795 shares at EUR 1.8656 per share to settle convertible bond amortisation payment. |
+0.0% |
| 02 Dec 25 | Routine | Grant of Options | |
| 01 Dec 25 | Board change | Appointment of CFO
Jurriaan Dekkers appointed CFO effective 1 December 2025; current CFO Yrjö Wichmann retiring end Q1 2026. |
+0.0% |
| 27 Nov 25 | Faron’s Financial Calendar for 2026
Faron announces its financial reporting calendar for 2026. |
+4.1% | |
| 24 Nov 25 | INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT
Faron intends to issue EUR 10 million second tranche of convertible bonds under HCM arrangement. |
+0.0% | |
| 28 Oct 25 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
Company issues 451,803 shares at EUR 1.8695 per share to settle advanced bond amortisation payment. |
−1.3% |
| 21 Oct 25 | Holding | Holding(s) In Company | |
| 20 Oct 25 | Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients
Updated Phase I/II BEXMAB data shows 85% ORR and 45% CR in treatment-naïve HR-MDS patients with 100% ORR in low blast count subgroup. |
+1.4% |
Company filings. Not investment advice.